FLT3 and cancer: From recent studies, it was confirmed that Cabozantinib specifically targets endothelial growth factor receptor types 1 (VEGFR-1) (6), endothelial growth factor receptor types 2 (VEGFR-2) (7), FMS-like tyrosine kinase 3 (FLT-3) (8); which ultimately results in the demotion of angiogenesis and proliferation of malignant tumour (9, 10).